Asset Details
Do you wish to reserve the book?
Does Curative Radiotherapy Impact Fatigue Onset in Prostate Cancer Patients? An Analysis of 1253 Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Does Curative Radiotherapy Impact Fatigue Onset in Prostate Cancer Patients? An Analysis of 1253 Patients
Do you wish to request the book?
Does Curative Radiotherapy Impact Fatigue Onset in Prostate Cancer Patients? An Analysis of 1253 Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Does Curative Radiotherapy Impact Fatigue Onset in Prostate Cancer Patients? An Analysis of 1253 Patients
2026
Overview
Background This study investigates the impact of radiotherapy (RT) on fatigue levels in prostate cancer (PC) patients, considering the significant physical and psychological impact of fatigue associated with cancer and its treatments. Methods PC patients undergoing a radical treatment from December 2002 to September 2022 were retrospectively evaluated. Fatigue was assessed using the Cancer Linear Analogue Scale (CLAS) across three dimensions: wellbeing (CLAS1), energy level (CLAS2), and daily activity performance (CLAS3), measured at baseline (T0), 1 month (T1), and 12 months (T2) post‐RT. Changes in CLAS scores ≥ 2 points from T0 were deemed clinically significant for RT‐induced fatigue. Results The cohort consisted of 1253 patients, with a median age of 72 years (range 45–90). Approximately 30% of patients experienced moderate or high levels of fatigue at baseline. At T1, RT‐related fatigue onset (decrease of CLAS1, 2, and 3 values) was observed in 10.8%, 14.3%, and 14.8% of patients, respectively. These figures slightly increased at T2 (12.7%, 18.8%, and 19.4%, respectively). Logistic regression identified hypofractionated RT, ADT, surgery, alcohol consumption, and higher‐grade toxicities as predictors of worsened fatigue across various dimensions. Conclusion In this extensive cohort of PC patients, approximately 30% experienced moderate to severe fatigue before initiating RT, with less than 20% reporting new or exacerbated fatigue post‐treatment. Factors including treatment‐related toxicities, hypofractionation, alcohol use, and ADT were significant contributors to fatigue. These findings underscore the complexity of managing fatigue in PC, highlighting the influence of both treatment modalities and lifestyle factors.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
